Seeking Novel Targets and Treatments in Immunology and Rare Diseases

Takeda Pharmaceutical are launching an open innovation initiative, inviting researchers to submit their ideas and technologies across five different focus areas, up to £60k / €70k / $100k (AUD). Summarised below are the interests of Takeda relating to Novel Targets and Treatments in Immunology and Rare Diseases. In the attached application form, each of these topics have been expanded upon to give further detail of proposals. 

Submissions should be relevant to one or more of the following titles:

• REF #8 Regulatory immune cell-focused research applicable to the treatment of neurodegenerative, autoimmune or rare diseases
• REF #9 Drug discovery for central nervous system diseases (neurodegenerative diseases, psychiatric disorders) aiming at control of central or peripheral immunity / inflammation
• REF #10 Development of CAR-engineered immune cells including T/NK cell products against novel solid and/or hematological malignancies targets
• REF #11 Research and development toward realization of innovative technology for next generation cellular cancer immuno-therapy
• REF #12 Innovative research to realize immune cell therapies by using cutting-edge technology (e.g. biomaterials, AI)
• REF #13 Small molecule approaches to hematological diseases e.g. sickle cell disease, hemophilia A and B

Global Eligibility: 

Only submissions from Europe and Australia will be eligible for this campaign.

How to Apply: 

 To view more details on each area of interest seeking proposals for funding, download an application form here.To submit your proposal, please visit discover.in-part.com, register, and submit as a Research Project under the appropriate Discover campaign.